New Schizophrenia Publication Co-Authored by Dr. Walling
Check out a new publication co-authored by David Walling, Ph.D., Chief Executive Officer and Principal Investigator at CNS Research.
Efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active-control ALPINE study. J Clin Psychiatry. 2020;81(3):19m13207.